Wednesday, August 19
Target and Amazon surge as drone delivery goes national
A blowout retail quarter and a massive drone delivery expansion gave markets plenty to cheer, but a defense giant's leadership scandal and a surprising sell-off in a beat-and-raise stock complicated the picture.
Top Stories
Target's tariff refund inflates a quarter that doesn't deserve a clean turnaround label
Target posted a stronger-than-expected quarter Wednesday, beating earnings estimates and raising its full-year outlook on the back of more store traffic, a revamped grocery section, and nearly a billion dollars in tariff refunds that gave the results a one-time lift.
The underlying momentum is genuine, but investors who want to call this a full turnaround will need to see whether the traffic gains hold once the tariff tailwind fades and trade policy uncertainty returns.
Amazon's drone delivery leap signals logistics is the next AI battleground
Amazon announced it will expand Prime Air drone delivery from 11 locations to nearly 500 U.S. cities by year-end, while separately revealing that its cloud AI business has crossed a $25 billion annual revenue run rate with triple-digit growth.
The two announcements together tell the same story: Amazon is betting that speed of delivery and speed of computation are the same competitive advantage, and it is now moving fast enough on both fronts to make that bet credible.
L3Harris's CEO ouster is a governance failure hiding in plain sight
L3Harris confirmed Wednesday that it removed CEO Chris Kubasik following an investigation into his conduct with a subordinate, with the Wall Street Journal reporting that women at the company had raised concerns about his behavior years before he was finally let go.
For a major defense contractor whose contracts depend on institutional trust, the fact that earlier complaints went unaddressed is more damaging than the departure itself.
Also Today
- TJX Companies: tariff refunds masking a soft underlying beat
- Toll Brothers held up on luxury buyers shrugging off rate pressure
- Regeneron wins rare FDA approval for bone disorder drug
Takeaway
Today's session was defined by a split between genuine business momentum and results that look cleaner than they are, with tariff refunds quietly inflating the retail earnings season in ways that will be harder to replicate.
The number to watch next is whether Keysight's $2 billion order backlog starts converting to revenue as supply constraints ease, which would confirm that AI infrastructure spending is as durable as the bulls insist.
